Compare HUBC & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | ACXP |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.6M |
| IPO Year | 2022 | 2021 |
| Metric | HUBC | ACXP |
|---|---|---|
| Price | $0.76 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | ★ 352.1K | 82.4K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $1.33 |
| 52 Week High | $7.00 | $8.34 |
| Indicator | HUBC | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 54.77 |
| Support Level | $0.11 | $1.36 |
| Resistance Level | $1.16 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 15.60 | 77.22 |
Hub Cyber Security Ltd is engaged in developing reliable quality assurance systems that support process and product enhancement and also operates in the industry of secured data fabric. The company serves various organizations and institutions operating in the security, electronics, aviation, telecommunications, and banking. The company has two operating segments: Product and Technology Segment and Professional Services Segment. The majority of revenue comes from the professional services segment, which provides data and cybersecurity and system security and reliability solutions and related services such as consulting, planning, integrating and ongoing servicing of cybersecurity, risk management, reliability and security projects and fully managed corporate cybersecurity services.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.